ArticleNPJ precision oncology2026
Deep learning-based spatiotemporal estimation of lesion changes for patient-level assessment of breast cancer lung metastases on longitudinal CT.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Clinical management of breast cancer lung metastasis is challenging because of the complexity of dynamic lesion assessment. Traditional methods based on RECIST1.1 rely on size measurement, and existing studies require image registration and are limited to lesion-level assessment. In this study, we proposed a patient-level spatiotemporal assessment framework without registration to comprehensively analyze multiple lesions evolvement based on longitudinal CT images. Our method considers metastatic lesions that vary in size and often overlap with complex structures such as blood vessels and bones, and avoids potential registration errors. Our method outperforms state-of-the-art methods on both the Peking Union Medical College Hospital breast cancer lung metastasis dataset and the publicly available dataset. The model also showed excellent performance in a multicenter validation across four medical centers. We established a patient-level metastatic breast cancer assessment framework, providing a practical solution for longitudinal treatment monitoring.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.